| Replicate Bioscience
Immunology & Inflammation Therapeutics · Drug Discovery
$20Mlatest round · Venture round · Feb 2021 · 5 yr ago
1backers · Apple Tree Partners
20team · US Form 5500 (plan participants) · Dec 2025 · 0% in a year
2021founded
Overview
Replicate Bioscience is pioneering novel self-replicating RNA (srRNA) technology to enable more treatment opportunities for more people.
Key facts
These are the key facts about | Replicate Bioscience on Alion as of Nov 13, 2026. | Replicate Bioscience is headquartered in San Diego, United States. It was founded in 2021. The latest round is Venture - Series Unknown of $20M, announced in 2021.
- Headquarters
- San Diego, United StatesAlion company profile, updated Sep 28, 2026
- Founded
- 2021Alion company profile, updated Sep 28, 2026
- Employees
- 50+Alion company profile, an estimated range
- Total raised
- $20MSum of 1 equity round Alion knows
- Latest round
- Venture - Series Unknown · $20M · Feb 4, 2021SEC Form D filing · sec.gov
Official records
Funding and backers
Total raised
$20M
1 round on record
Latest round
$20M
Venture round · Feb 2021 · 5 yr ago
Team
20
US Form 5500 (plan participants) · Dec 2025 · 0% in a year
Backers
1
Apple Tree Partners
The money's age
Long since its last round
69 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Feb 2021 | $20M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | Replicate Bioscience, Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Michael EhlersExecutive Officer, DirectorSEC Form D
Nathaniel WangExecutive Officer, DirectorSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
SynthBiome replicating the dynamic nature of human physiology in test tubes for better drug development and treatment selection.
AltruBio. Developing safer, more durable treatments to improve the lives of patients.
To find the right drug for the right target…. Deep Apple Therapeutics is discovering new small-molecule therapeutics with unprecedented…
We are BioPhy, a healthcare fintech company committed to enhancing outcomes for patients and creating value for investors using our…
Soricimed Biopharma is a clinical stage drug development company dedicated to novel trageted treatments for cancer.
Xylo is pioneering next-generation therapeutics designed to rewire neural circuits and restore brain function. Discover our innovative…
Financials
Total raised
$20M
Latest round
Venture - Series Unknown
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Venture - Series Unknown | 2021 | $20M | Details |
People
Michael Ehlers
Executive Officer, Director
Nathaniel Wang
Executive Officer, Director
Seth Harrison
Director
Joseph Yanchik
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Apple Tree PartnersVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
Shared investors
News
San Diego based Replicate Bioscience believes that self-replicating RNA has key advantages
Read more
Report
Replicate Bioscience Awarded Grant to Advance srRNA Vaccine Candidates for Tuberculosis
Company receives grant from the Gates Foundation to develop srRNA vaccine candidates for tuberculosis, subject to humanitarian licensing terms SAN DIEGO, June 19, 2026 /PRNewswire/ - Replicate Bioscience, a clinical-stage company pioneering novel self-rep
Read more
Report
Report
Report
Replicate Bioscience Awarded Grants to Develop New srRNA Vaccines for HIV and Malaria
Company to receive approximately $7 million in funding from the Gates Foundation to use its srRNA platform to develop malaria and HIV candidates to address two of the world's most persistent public health burdens, subject to humanitarian licensing terms S
Read more
Report
Replicate Bioscience Announces Publication of Promising New Phase 1 Durability Data for Its srRNA Vaccine Candidate RBI-4000
Replicate Bioscience, a clinical-stage company pioneering novel self-replicating RNA (srRNA) technology for applications across infectious disease, immunology, and other therapeutic areas, today announced that long term immunogenicity data from the Phase
Read more
Report
Replicate Bioscience Announces Partnership with Novo Nordisk to Unlock Self-Replicating RNA Therapies for Obesity and Diabetes
Replicate Bioscience, a clinical-stage company pioneering next-generation self-replicating RNA (srRNA) technology for applications across infectious disease, immunology, and other therapeutic areas, today announced a multi-year research collaboration with
Read more
Report
Report
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
San Diego
United States
HQ
50-200 est. staff
How to cite this page
Alion, "| Replicate Bioscience: key facts", as of Nov 13, 2026. https://alion.io/company/replicatebioscience
These figures are published under a free licence. You may reuse them, including commercially, as long as you credit Alion and link back to this page. CC BY-SA 4.0